A Phase 1 interventional study of amlodipine/telmisartan/combination in Healthy, sponsored by Boehringer Ingelheim. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-07-24.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To determine the pharmacokinetic profile of 80 mg telmisartan / 5 mg amlodipine (T80/A5) dose combination after single dose in healthy Chinese subjects.
To determine whether a pharmacokinetic interaction exists between telmisartan and amlodipine, following single doses of 80mg telmisartan (T80), and 5 mg amlodipine (A5) tablet alone and in combination, in healthy Chinese subjects.
To evaluate the safety and tolerability of T80 and A5 alone and in combination in healthy Chinese subjects.
Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
all patients will be assigned to 6 treatment sequences. cross-over design was adopted to ensure each patient would take amlodipine/telmisartan/combination single dose in randomized order
Drug: amlodipine/telmisartan/combination
patient would take amlodipine(5mg)/telmisartan(80mg)/combination(T80+A5mg) single dose in random order, and each dosage will be separated in 21 days interval.
Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz)
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
The Maximum Observed Plasma Concentration (Cmax) of Telmisartan
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
AUC_0-tz of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
AUC_0-∞ of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Cmax of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days of wash-outs
Time to Attain Cmax (Tmax) of Telmisartan
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Terminal Rate Constant in Plasma (λz) of Telmisartan
reflect the speed of drug elimination in vivo
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po)
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Elimination Half-life (t_½) of Telmisartan
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F)
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Tmax of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
λz of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
MRT_po of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
t_½ of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
CL/F of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
V_z/F of Amlodipine
Time frame: 3 periods of single-dose treatment (8 days of sampling) separated by 21 days wash-outs
Number of Participants With at Least One Treatment Emergent Adverse Event
Time frame: 4 weeks
Number of Participants With Clinically Relevant Findings in Electrocardiogram (ECG), Vital Signs, Physical Finding or Laboratory Finding Abnormalities
Time frame: 4 weeks
| Milestone | All Participants |
|---|---|
| Started | 28 |
| Received telmisartan 80mg | 27 |
| Received telmisartan 80mg,amlodipine 5mg | 27 |
| Received amlodipine 5mg | 26 |
| Completed | 25 |
| Not completed | 3 |
| Withdrew: Adverse event | 2 |
| Withdrew: Lost to follow-up | 1 |
| ng·h/mL | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Area Under the Concentration-time Curve of Telmisartan in Plasma Over the Time Interval From 0 to the Time of the Last Quantifiable Data Point (AUC_0-tz) | 3200 ± 74.7 | 2940 ± 94.4 |
| ng·h/mL | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Area Under the Plasma Concentration-time Curve From the Time of Dosing to Infinity (AUC_0-∞) of Telmisartan | 3420 ± 82.5 | 3140 ± 98.5 |
| ng/mL | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| The Maximum Observed Plasma Concentration (Cmax) of Telmisartan | 461 ± 59.9 | 480 ± 78.3 |
| ng·h/mL | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| AUC_0-tz of Amlodipine | 206 ± 28.6 | 192 ± 31 |
| ng·h/mL | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| AUC_0-∞ of Amlodipine | 225 ± 27.1 | 210 ± 30.9 |
| ng/mL | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| Cmax of Amlodipine | 4.72 ± 21.7 | 4.43 ± 27.3 |
| h | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Time to Attain Cmax (Tmax) of Telmisartan | 1.22 ± 0.58 | 1.16 ± 0.76 |
reflect the speed of drug elimination in vivo
| 1/h | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Terminal Rate Constant in Plasma (λz) of Telmisartan | 0.0305 ± 0.0114 | 0.0323 ± 0.0124 |
| h | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Mean Residence Time of Telmisartan in the Body After Oral Administration (MRT_po) | 20.0 ± 4.8 | 18.4 ± 5.7 |
| h | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Elimination Half-life (t_½) of Telmisartan | 27.0 ± 13.7 | 25.0 ± 10.7 |
| L/h | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Apparent Clearance of Telmisartan in Plasma Following Extravascular Administration (CL/F) | 31.0 ± 21.6 | 37.3 ± 39.7 |
| L | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg |
|---|---|---|
| Apparent Volume of Distribution During the Terminal Phase λz Following an Extravascular Administration (V_z/F) of Telmisartan | 1021 ± 697 | 1135 ± 1018 |
| h | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| Tmax of Amlodipine | 6.88 ± 1.74 | 7.20 ± 1.63 |
| 1/h | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| λz of Amlodipine | 0.0305 ± 0.0114 | 0.0323 ± 0.0124 |
| h | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| MRT_po of Amlodipine | 44.3 ± 7.0 | 43.7 ± 7.6 |
| h | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| t_½ of Amlodipine | 38.8 ± 7.6 | 38.6 ± 7.5 |
| L/h | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| CL/F of Amlodipine | 22.7 ± 6.3 | 25.1 ± 7.9 |
| L | Telmisartan 80mg, Amlodipine 5mg | Amlodipine 5mg |
|---|---|---|
| V_z/F of Amlodipine | 1241 ± 313 | 1353 ± 369 |
| Participants | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg | Amlodipine 5mg |
|---|---|---|---|
| Number of Participants With at Least One Treatment Emergent Adverse Event | 4 | 2 | 4 |
| Participants | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg | Amlodipine 5mg |
|---|---|---|---|
| ECG abnormalities | 0 | 0 | 0 |
| Vital signs abnormalities | 0 | 0 | 0 |
| Physical finding abnormalities | 0 | 0 | 0 |
| Laboratory finding abnormalities | 1 | 1 | 0 |
Collected over 4 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Telmisartan 80mg, Amlodipine 5mg | — | 0/27 (0%) | 2/27 (7.4%) |
| Telmisartan 80mg | — | 0/27 (0%) | 1/27 (3.7%) |
| Amlodipine 5mg | — | 0/26 (0%) | 3/26 (11.5%) |
| Event | Telmisartan 80mg, Amlodipine 5mg | Telmisartan 80mg | Amlodipine 5mg |
|---|---|---|---|
| InfluenzaInfections and infestations | 2/27 | 1/27 | 3/26 |
| Age, Continuous(Years) | All Participants |
|---|---|
| Mean | 24 ± 2.0 |
| Sex: Female, Male(Participants) | All Participants |
|---|---|
| Female | 10 |
| Male | 18 |
The record gives a start of Aug 2010 and a primary completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2012, 1 year 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.